CommentDelamanid: does it have a role in tuberculosis treatment?
References (11)
- et al.
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial
Lancet Respir Med
(2019) WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrugresistant Tuberculosis. WHO/HTM/TB/2017.20
- et al.
Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline
Eur Respir J
(2017) - et al.
Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence
Eur Respir J
(2017) - et al.
Multidrug-resistant tuberculosis and culture conversion with bedaquiline
N Engl J Med
(2014)
There are more references available in the full text version of this article.
Cited by (4)
Targeting polyketide synthase 13 for the treatment of tuberculosis
2023, European Journal of Medicinal ChemistryNew regimens and new medications in the treatment of tuberculosis: Keeping step?
2021, Kliniceskaa Mikrobiologia i Antimikrobnaa HimioterapiaCurrent and future treatments for tuberculosis
2020, The BMJTreatment of drug-resistant tuberculosis an official ATS/CDC/ERS/IDSA clinical practice guideline
2019, American Journal of Respiratory and Critical Care Medicine
© 2019 Elsevier Ltd. All rights reserved.